Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
In France, 50% of hepatitis C virus carriers develop chronic clinical hepatitis, which may
lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is
constant after transplantation and recurrence causes chronic liver disease in 50 to 80% of
cases. The aim of this study is to assess the efficacy of cyclosporin on C virological
response. Patients included in the Transpeg 1 study and non-responder or with a recurrent
disease will be switched from their tacrolimus therapy to cyclosporin, in association with a
1 year peginterferon alfa-2a / ribavirin bitherapy. Efficacy will be assessed by the
percentage of patients with a negative qualitative PCR after 19 months of cyclosporin
treatment.